MIPSS Plus

MIPSS‑Plus is a myelofibrosis prognostic model that integrates clinical factors with high‑risk molecular mutations to stratify survival risk.

Moderate Anemia (9-10.9 g/dL men, 8-9.9 g/dL women)
No0Yes+1
Severe anemia (< 9g/dl men, < 8 g/dl women)
No0Yes+2
Constitutional symptoms
No0Yes+2
Circulating blasts ≥ 2%
No0Yes+1
Absence of CALR type 1-like mutation
No0Yes+2
HMR category
No0Yes+2
Two or more HMR mutations
No0Yes+3
Unfavorable karyotype
No0Yes+3
Very high-risk karyotype
No0Yes+4

Indications d'utilisation

Used for primary myelofibrosis patients ≤70 years to integrate clinical factors, cytogenetics, and high‑molecular‑risk mutations to predict overall survival and refine transplant decision‑making. Provides four risk categories with markedly differing 5‑year OS (91% to 7%) 1 [Level I evidence]. Guides timing of allogeneic HCT, with high/very‑high‑risk groups showing clear post‑transplant survival benefit 2 [Level II evidence].

Informations et précautions

Stratifies primary myelofibrosis by combining clinical features with adverse mutations and cytogenetics, enabling finer separation of intermediate‑ and high‑risk groups and guiding HSCT timing (strong survival discrimination in 805‑patient cohort 1 [Level I evidence]). Use cautiously: requires full NGS and cytogenetics, may overestimate risk in older or comorbid patients, and added HMR mutations (CBL/NRAS/KRAS/RUNX1/TP53) do not improve performance 2 [Level II evidence].